Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441758 | 1.00 | SLC22A12 (0.67) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL19435501 | 0.86 | SLC22A12 (0.55) | SLC22A12 | |
| SCHEMBL23129626 | 0.85 | SLC22A12 (0.57) | SLC22A12 | |
| SCHEMBL17899839 | 0.82 | SLC22A12 (0.70) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL17899890 | 0.80 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL17899920 | 0.77 | SLC22A12 (0.78) | SLC22A12 | |
| SCHEMBL29441759 | 0.77 | SLC22A12 (0.78) | SLC22A12 | |
| SCHEMBL9994029 | 0.77 | SLC22A12 (0.69) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL28387514 | 0.77 | SLC22A12 (0.67) | SLC22A12 | |
| SCHEMBL17899861 | 0.77 | SLC22A12 (1.00) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11278528-B2 | Activator of peroxisome proliferator-activated receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-03-22 | — | — | US | claimed |
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | claimed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | claimed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | claimed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | claimed |
| JP-2023123704-A | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | 日本ケミファ株式会社 | 2023-09-05 | — | — | JP | disclosed |
| US-11278528-B2 | Activator of peroxisome proliferator-activated receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-03-22 | — | — | US | disclosed |
| US-11278528-B2 | Activator of peroxisome proliferator-activated receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| EP-3705120-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-20200268719-A1 | ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200268719-A1 | ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
| WO-2016108282-A1 | URAT1 INHIBITOR | 日本ケミファ株式会社 | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268719-A1 | ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | PPARA, PPARG, PPARD | SLC22A12 2004/4885SLC22A6 1911/4885SLC22A11 1550/4885 |
| US-11278528-B2 | Activator of peroxisome proliferator-activated receptor | PPARA, PPARG, PPARD | SLC22A12 2004/4885SLC22A6 1911/4885SLC22A11 1550/4885 |
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | SLC22A12 512/4885SLC22A6 534/4885SLC22A11 263/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | SLC22A12 500/4885SLC22A6 528/4885SLC22A11 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.